1. Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.
- Author
-
Uzunoglu FG, Kaufmann C, Wikman H, Güngör C, Bohn BA, Nentwich MF, Reeh M, Pantel K, Bockhorn M, Kutup A, Mann O, Izbicki JR, and Vashist YK
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma mortality, Adenocarcinoma secondary, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung secondary, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell secondary, Female, Follow-Up Studies, Genotype, Humans, Lung Neoplasms genetics, Lung Neoplasms mortality, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Prognosis, Prospective Studies, Risk Factors, Survival Rate, Biomarkers, Tumor genetics, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung mortality, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local mortality, Polymorphism, Genetic genetics, Vascular Endothelial Growth Factor Receptor-2 genetics
- Abstract
Purpose: VEGFR-2 gene displays several functional germline polymorphisms with impact on VEGFR-2 mediated angiogenesis. Our purpose was to evaluate VEGFR-2 polymorphisms as prognostic markers for tumor recurrence and overall survival (OS) in non-small-cell lung cancer (NSCLC)., Methods: In total, 209 Caucasian patients who had been surgically treated for NSCLC between 1996 and 2010 were included in this study. Genotyping of peripheral blood cells was performed by TaqMan® genotyping assays or polymerase chain reaction for five VEGFR-2 polymorphisms. Chi- square test, Kaplan-Meier estimator, and Cox regression hazard model were used to assess the prognostic value of VEGFR-2 polymorphisms., Results: VEGFR-2+4422 (AC)10-14 polymorphism was identified as a positive prognostic marker for time to metastasis (11/12 vs. 11/11 (AC) repeats: hazard ratio (HR), 0.28; 95% confidence interval (CI), 0.11-0.75; p=0.012) and OS (11/12 vs. 11/11 (AC) repeats: HR, 0.41; 95% CI, 0.21-0.82; p=0.012) in squamous cell carcinoma. For adenocarcinoma, VEGFR-2-906 C>T (C/T vs. CC: HR, 0.19; 95% CI, 0.43-0.82; p=0.027) and VEGFR-2-271 G>A (G/A vs. G/G: HR, 0.25; 95% CI, 0.07-0.86; p=0.027) predicted longer time to local recurrence and VEGFR-2-906 C>T was a predictor for better OS (T/T vs. C/C: HR, 0.28; 95% CI, 0.09-0.84; p=0.024)., Conclusions: VEGFR2 germline polymorphisms predict tumor recurrence and OS in NSCLC.
- Published
- 2012
- Full Text
- View/download PDF